Leerink Partnrs Has Negative Outlook of BBIO FY2028 Earnings

BridgeBio Pharma, Inc. (NASDAQ:BBIO) – Leerink Partnrs cut their FY2028 earnings per share (EPS) estimates for shares of BridgeBio Pharma in a report issued on Tuesday, November 12th. Leerink Partnrs analyst M. Foroohar now expects that the company will post earnings of $4.31 per share for the year, down from their previous estimate of $4.38. The consensus estimate for BridgeBio Pharma’s current full-year earnings is ($2.59) per share.

Several other brokerages have also recently issued reports on BBIO. HC Wainwright reaffirmed a “buy” rating and set a $43.00 target price on shares of BridgeBio Pharma in a research note on Friday, October 25th. Piper Sandler started coverage on shares of BridgeBio Pharma in a report on Wednesday, September 4th. They issued an “overweight” rating and a $46.00 price objective for the company. JPMorgan Chase & Co. lowered their target price on BridgeBio Pharma from $46.00 to $43.00 and set an “overweight” rating on the stock in a report on Wednesday, August 7th. Evercore ISI dropped their price target on BridgeBio Pharma from $50.00 to $45.00 and set an “outperform” rating for the company in a research report on Wednesday, August 7th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $70.00 price objective on shares of BridgeBio Pharma in a research report on Monday, September 16th. Two equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $47.50.

BridgeBio Pharma Stock Performance

Shares of NASDAQ:BBIO traded up $0.63 during trading on Thursday, reaching $25.42. The stock had a trading volume of 192,863 shares, compared to its average volume of 1,834,889. BridgeBio Pharma has a 1-year low of $21.62 and a 1-year high of $44.32. The stock has a market cap of $4.78 billion, a PE ratio of -10.29 and a beta of 1.09. The business has a fifty day moving average price of $25.78 and a 200-day moving average price of $26.44.

Insider Buying and Selling at BridgeBio Pharma

In other news, major shareholder Genetic Disorder L.P. Kkr sold 5,800,000 shares of the company’s stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $25.75, for a total value of $149,350,000.00. Following the transaction, the insider now directly owns 25,260,971 shares in the company, valued at approximately $650,470,003.25. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, major shareholder Genetic Disorder L.P. Kkr sold 5,800,000 shares of BridgeBio Pharma stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $25.75, for a total value of $149,350,000.00. Following the completion of the transaction, the insider now owns 25,260,971 shares in the company, valued at approximately $650,470,003.25. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Brian C. Stephenson sold 4,155 shares of the stock in a transaction on Monday, August 19th. The shares were sold at an average price of $24.69, for a total value of $102,586.95. Following the completion of the sale, the chief financial officer now owns 85,192 shares in the company, valued at approximately $2,103,390.48. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 5,831,544 shares of company stock valued at $150,128,821 over the last 90 days. 24.66% of the stock is owned by insiders.

Institutional Trading of BridgeBio Pharma

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Profund Advisors LLC raised its stake in BridgeBio Pharma by 1.1% during the 2nd quarter. Profund Advisors LLC now owns 51,029 shares of the company’s stock worth $1,293,000 after acquiring an additional 555 shares in the last quarter. American International Group Inc. raised its position in BridgeBio Pharma by 1.0% in the first quarter. American International Group Inc. now owns 57,491 shares of the company’s stock worth $1,778,000 after acquiring an additional 565 shares in the last quarter. Bfsg LLC boosted its holdings in BridgeBio Pharma by 175.6% during the second quarter. Bfsg LLC now owns 1,240 shares of the company’s stock worth $31,000 after buying an additional 790 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its stake in shares of BridgeBio Pharma by 17.7% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 5,322 shares of the company’s stock worth $135,000 after acquiring an additional 801 shares in the last quarter. Finally, Amalgamated Bank grew its holdings in BridgeBio Pharma by 24.7% in the second quarter. Amalgamated Bank now owns 4,863 shares of the company’s stock valued at $123,000 after purchasing an additional 962 shares during the last quarter. 99.85% of the stock is currently owned by institutional investors and hedge funds.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.